Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Key Highlights
- ➤Acadia will present Phase 2 remlifanserin efficacy and safety data at CTAD 2026
- ➤RADIANT evaluates remlifanserin for hallucinations and delusions in Alzheimer’s disease psychosis
- ➤Acadia will present biomarker heterogeneity findings among patients meeting clinical ADP criteria
- ➤Remlifanserin is being developed for Alzheimer’s disease psychosis and Lewy body dementia psychosis
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's presentations include an oral presentation featuring findings from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin in patients with Alzheimer's disease psychosis, as well as a poster presentation examining biomarker heterogeneity among patients meeting clinical criteria for ADP. Collectively, these presentations reflect Acadia's commitment to advancing the understanding and treatment of psychosis associated with Alzheimer’s disease.
Get started
Create a free account to read the full story.